Mechanistic description
TREM2 agonism promotes microglial phagocytosis and metabolic reprogramming, shifting microglia from disease-associated (DAM) to homeostatic state. AL002c (Alector) already in Phase II trials, making this the most translation-ready hypothesis.
Mechanism / pathway
- TREM2
- neurodegeneration
Evidence for (4)
TREM2 R47H variant increases AD risk ~3-fold
TREM2-deficient mice show impaired microglial enclosure of amyloid plaques
Human PET imaging shows TREM2 expression correlates with amyloid burden
AL002c shows efficacy in 5xFAD mice
Evidence against (3)
DAM microglia can prune excitatory synapses, not just plaques
R47H is loss-of-function - pharmacologic agonism may not recapitulate endogenous activation
Risk alleles explain only ~3% of AD cases
Evidence matrix
Supporting
- TREM2 R47H variant increases AD risk ~3-fold PMID:24121985
- TREM2-deficient mice show impaired microglial enclosure of amyloid plaques PMID:29548884
- Human PET imaging shows TREM2 expression correlates with amyloid burden PMID:31253634
- AL002c shows efficacy in 5xFAD mice PMID:32109293
Contradicting
- DAM microglia can prune excitatory synapses, not just plaques PMID:30742032
- R47H is loss-of-function - pharmacologic agonism may not recapitulate endogenous activation PMID:24121985
- Risk alleles explain only ~3% of AD cases PMID:population_studies
Cite this hypothesis
Cite this hypothesis
etl-backfill (2026). Microglial TREM2 Activation Reduces Amyloid-Associated Neurotoxicity. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-b9794c8e29
@misc{scidex_hypothesis_hb9794c8,
title = {Microglial TREM2 Activation Reduces Amyloid-Associated Neurotoxicity},
author = {etl-backfill},
year = {2026},
howpublished = {SciDEX hypothesis},
url = {https://prism.scidex.ai/hypotheses/h-b9794c8e29},
note = {SciDEX artifact hypothesis:h-b9794c8e29}
}